AstraZeneca, Takeda sign $400m deal for Parkinson’s therapy
AstraZeneca and Takeda are to jointly develop and commercialise an experimental therapy for Parkinson’s disease.
Read More
Tag: MEDI1341
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
